Visit additional Tabor Communication Publications
May 01, 2008
GAINESVILLE, Fla., May 1 -- University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and -- in a remarkable finding -- prevents damage to the heart and kidneys in rats with persistent hypertension.
The findings, which appear in today’s (May 1) edition of the American Heart Association journal Hypertension, could lead to a new class of antihypertensive drugs designed to address two major problems associated with cardiovascular disease: high blood pressure and the tissue damage associated with it, known as fibrosis.
“When people have heart attacks (or suffer from hypertension) the blood vessels get more rigid,” said study author David Ostrov, an assistant professor in the UF College of Medicine’s department of pathology, immunology and laboratory medicine. “We discovered a compound that reverses the fibrosis that makes the blood vessels more rigid.”
The American Heart Association estimates that 72 million people in the United States have high blood pressure, a major risk factor for stroke, heart attack and death.
Angiotensin-converting enzyme plays a key role in the development of high blood pressure. It produces angiotensin II, a potent hormone that triggers the condition and contributes to the development of cardiovascular disease by constricting blood vessels, causing blood pressure to rise. That’s why millions of Americans with hypertension and cardiovascular disease take ACE inhibitors. But these drugs have limited capacity to repair heart function and to reverse tissue damage.
In contrast, the enzyme ACE2 not only lowers levels of angiotensin II but also converts it to a hormone that helps protect the cardiovascular system.
“Only recently has it come to be appreciated that ACE and ACE2 play a very important role in balancing the activity of the other one to maintain normal blood pressure,” Ostrov said. “They work in harmony.”
Hypothesizing that activating ACE2 could be beneficial, UF scientists set out to discover a compound that enhances the enzyme’s activity.
Researchers used one of the world’s most powerful supercomputers to process 140,000 prospective drug compounds in a matter of weeks. The computer predicted which molecules would be most likely to enhance the activity of ACE2, rotating them in thousands of different orientations to see how they would bind to certain pockets on the enzyme’s surface.
“This project had a very small likelihood of succeeding because it’s much easier to inhibit activity rather than to enhance it. By analogy, it’s easier to break something than to build it,” Ostrov said. “If you consider the structure of an enzyme’s active site it’s easy to see that if you plug up the active site it’s not going to work. But how can one make the enzyme actually work better? This seemed to be a very significant challenge we were probably not likely to overcome. We tried anyway.”
And it worked.
“That in itself is a significant accomplishment because no one has ever specifically identified a compound that enhances the activity of an enzyme using a rational structure-based approach,” he said. “In other words, no one has ever done this before on purpose. People have discovered molecules that enhance the activity of enzymes by trial and error, but no group has ever done it in a specifically pointed way like this.”
Ostrov said the enzyme exists in two forms: like a Pac-Man with a mouth that has chomped closed, and like a Pac-Man with a mouth that remains wide open. The molecule that worked best fit in a structural pocket in the enzyme’s open conformation.
“So in other words, stabilizing the open conformation may be the reason why we enhance the activity of the enzyme,” he said
After hitting on the “lead” compound, UF researchers then tested it in hypertensive rats that had developed fibrosis of the heart and kidney. The animals received the drug for two weeks. Tissue samples from treated animals revealed a significant decrease in fibrosis of the heart, kidney and blood vessels, said Ostrov, who described the findings as “striking and reproducible.”
The study was funded by grants from the National Institutes of Health and the American Heart Association and was a collaborative effort of the UF colleges of Medicine, Pharmacy and Liberal Arts and Sciences. Researchers also included Mohan Raizada, a distinguished professor of physiology and functional genomics, Michael J. Katovich, a professor of pharmacodynamics, and Ronald K. Castellano, an assistant professor of chemistry, among others.
Early results also show the compound inhibits inflammation, which has significant implications for a number of human diseases, including autoimmune diseases such as type 1 diabetes and rheumatoid arthritis as well as other diseases involving fibrosis, such as Alzheimer’s, Ostrov said.
Additional research will continue to explore the compound’s effectiveness in animals and humans.
Source: University of Florida
Contributing commentator, Andrew Jones, offers a break in the news cycle with an assessment of what the national "size matters" contest means for the U.S. and other nations...
Today at the International Supercomputing Conference in Leipzing, Germany, Jack Dongarra presented on a proposed benchmark that could carry a bit more weight than its older Linpack companion. The high performance conjugate gradient (HPCG) concept takes into account new architectures for new applications, while shedding the floating point....
Not content to let the Tianhe-2 announcement ride alone, Intel rolled out a series of announcements around its Knights Corner and Xeon Phi products--all of which are aimed at adding some options and variety for a wider base of potential users across the HPC spectrum. Today at the International Supercomputing Conference, the company's Raj....
Jun 19, 2013 |
Supercomputer architectures have evolved considerably over the last 20 years, particularly in the number of processors that are linked together. One aspect of HPC architecture that hasn't changed is the MPI programming model.
Jun 18, 2013 |
The world's largest supercomputers, like Tianhe-2, are great at traditional, compute-intensive HPC workloads, such as simulating atomic decay or modeling tornados. But data-intensive applications--such as mining big data sets for connections--is a different sort of workload, and runs best on a different sort of computer.
Jun 18, 2013 |
Researchers are finding innovative uses for Gordon, the 285 teraflop supercomputer housed at the San Diego Supercomputer Center (SDSC) that has a unique Flash-based storage system. Since going online, researchers have put the incredibly fast I/O to use on a wide variety of workloads, ranging from chemistry to political science.
Jun 17, 2013 |
The advent of low-power mobile processors and cloud delivery models is changing the economics of computing. But just as an economy car is good at different things than a full size truck, an HPC workload still has certain computing demands that neither the fastest smartphone nor the most elastic cloud cluster can fulfill.
Jun 14, 2013 |
For all the progress we've made in IT over the last 50 years, there's one area of life that has steadfastly eluded the grasp of computers: understanding human language. Now, researchers at the Texas Advanced Computing Center (TACC) are utilizing a Hadoop cluster on its Longhorn supercomputer to move the state of the art of language processing a little bit further.
05/10/2013 | Cleversafe, Cray, DDN, NetApp, & Panasas | From Wall Street to Hollywood, drug discovery to homeland security, companies and organizations of all sizes and stripes are coming face to face with the challenges – and opportunities – afforded by Big Data. Before anyone can utilize these extraordinary data repositories, however, they must first harness and manage their data stores, and do so utilizing technologies that underscore affordability, security, and scalability.
04/15/2013 | Bull | “50% of HPC users say their largest jobs scale to 120 cores or less.” How about yours? Are your codes ready to take advantage of today’s and tomorrow’s ultra-parallel HPC systems? Download this White Paper by Analysts Intersect360 Research to see what Bull and Intel’s Center for Excellence in Parallel Programming can do for your codes.
Join HPCwire Editor Nicole Hemsoth and Dr. David Bader from Georgia Tech as they take center stage on opening night at Atlanta's first Big Data Kick Off Week, filmed in front of a live audience. Nicole and David look at the evolution of HPC, today's big data challenges, discuss real world solutions, and reveal their predictions. Exactly what does the future holds for HPC?
Join our webinar to learn how IT managers can migrate to a more resilient, flexible and scalable solution that grows with the data center. Mellanox VMS is future-proof, efficient and brings significant CAPEX and OPEX savings. The VMS is available today.